Skip To Main Content
Campus
  • Tiede
  • Koulutukset
  • Artikkelit
  • Materiaalit
Campus
  • Tiede
  • Koulutukset
  • Artikkelit
  • Materiaalit

Koulutusvideot

Järjestä

Suodattimet

Nollaa
  • Terapia-alue
The Hematology Podcast - Season 2

The Hematology Podcast - Season 2

Lue lisää
The Hematology Podcast - Season 3

The Hematology Podcast - Season 3

Lue lisää
The Hematology Podcast - Season 4

The Hematology Podcast - Season 4

Lue lisää
Hot topics in atopic dermatitis: Longterm Control in AD

Hot topics in atopic dermatitis: Longterm Control in AD

Lue lisää
Early Detection and Surveillance of Autoimmune Type 1 Diabetes

Early Detection and Surveillance of Autoimmune Type 1 Diabetes

Lue lisää
Atopic Dermatitis in Melanin-Rich Skin - A DermTalks Webinar

Atopic Dermatitis in Melanin-Rich Skin - A DermTalks Webinar

Lue lisää
Cardiovascular management in patients with Fabry disease

Cardiovascular management in patients with Fabry disease

Management in Patients with Fabry Disease.

Lue lisää
Preventive Cardiology: Key Insights from Professor Michal Vrablik

Preventive Cardiology: Key Insights from Professor Michal Vrablik

Lue lisää
Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi

Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi

Lue lisää
Personalized approach in T2D is key for success

Personalized approach in T2D is key for success

The Sanofi webinar ‘Act Now for Impact: Glycemic Control and Beyond’ focuses on recent advancements in treating type 2 diabetes (T2D), emphasizing a personalized approach for better outcomes. Prof. Frank Nobels (Belgium), prof. De Galan (the Netherlands) and Prof Björn Eliasson (Sweden) addressed various aspects of T2D treatment in the present era.

Lue lisää
EADV24 Highlights

EADV24 Highlights

Lue lisää
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Lue lisää